Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
With global WEEE and EPR regulations undergoing significant reforms, particularly with new producer definitions and stricter compliance requirements taking effect through 2026, how should a medical de...
As the medical device industry anticipates potential shifts in global biocompatibility standards around 2026, how can manufacturers move beyond baseline qualifications, such as general quality system ...
With key regulatory deadlines approaching for medical devices placed on the Great Britain market, how should a non-UK manufacturer strategically evaluate and select a UK Responsible Person (UKRP)? Bey...
With significant updates to regulations often having multi-year transition periods, what is a robust framework for cosmetic manufacturers to manage the evolving responsibilities of the EU Responsible ...
With significant global reforms to Waste Electrical and Electronic Equipment (WEEE) and Extended Producer Responsibility (EPR) frameworks expected through 2026, how can medical device manufacturers es...
With new global biocompatibility standards anticipated around 2026, medical device manufacturers face uncertainty in selecting long-term testing partners. Choosing a lab based solely on current accred...
With the UK's medical device regulatory framework evolving and key deadlines approaching, many non-UK manufacturers are re-evaluating their strategy for maintaining market access in Great Britain. The...
Given the significant updates to EU cosmetic regulations anticipated for 2026, how should a non-EU manufacturer conduct a comprehensive evaluation to select a Responsible Person (RP) that extends beyo...
For a non-EU company offering an AI-driven service, such as a health-tech application, that processes the personal data of EU residents, the upcoming EU AI Act introduces a new compliance layer alongs...
With significant updates to the ISO 10993 series of biocompatibility standards anticipated around 2025-2026, medical device manufacturers face uncertainty, particularly before global regulatory bodies...
When budgeting for a UK Responsible Person (UKRP) ahead of upcoming compliance deadlines, what specific factors and service-level components contribute to the overall cost, beyond a basic annual retai...
For non-EU medical device manufacturers, selecting an EU Authorised Representative (AR) is a critical step for market access under the Medical Device Regulation (MDR). Beyond simply fulfilling a legal...
When developing a long-range strategic plan for a novel Class II diagnostic device, such as an acute kidney injury test system falling under 21 CFR 862.1220, what are the critical non-financial resour...
For UK-based medical device manufacturers, appointing an EU Authorized Representative (AR) is a critical step for placing products on the European Union market. While direct costs vary, understanding ...
As the United Kingdom’s medical device regulatory framework continues to evolve, what are the key practical and strategic considerations for non-UK manufacturers when selecting or re-assessing their U...
For a cosmetic brand preparing for the significant EU regulatory updates anticipated for 2026, what does a comprehensive due diligence process for selecting a new Responsible Person (RP) entail, beyon...
When preparing a premarket submission for a connected medical device, such as an integrated continuous glucose monitoring system (iCGM) under 21 CFR 862.1355 or a novel diagnostic test system, how can...
When a non-EU manufacturer plans to place a medical device on the European market, appointing an EU Authorized Representative (AR) is a mandatory step under the Medical Device Regulation (MDR). While ...
Under the Modernization of Cosmetics Regulation Act (MoCRA), the role and responsibilities of a U.S. Agent for foreign cosmetic facilities have expanded significantly beyond serving as a simple point ...
With new regulatory expectations for the European cosmetics market anticipated around 2026, how should a non-EU brand strategically evaluate and select a Responsible Person (RP) to ensure not just mar...